X hits on this document

Word document

FOOD AND DRUG ADMINISTRATION - page 196 / 263

578 views

0 shares

0 downloads

0 comments

196 / 263

1

the risk in the newborn I've already mentioned.

My concern is that the current assessment of bioequivalence is not adequately sensitive to detect these small differences that matter.  These are the real concerns and experts need to decide on a new approach that will address these concerns.  Anything less, such as continuing the current bioequivalence standard, would be a disservice to we practicing physicians and our patients.

I'd like to turn it over now to Dr. Granneman who will demonstrate how the current bioequivalence criteria perpetuate presumptions of bioequivalence that create the potential for the adverse clinical consequences that you heard about from all of the physician speakers this morning.

Thank you.

DR. GRANNEMAN:  I'd like to thank the FDA and the committee for inviting us to talk about the results of our study and various baseline correction procedures.

Although we will spend a lot of time talking about the ways that you can correct for endogenous T4 products, there's a larger question that we have to consider.  Ultimately, we have to ask the question, does

Document info
Document views578
Page views578
Page last viewedMon Dec 05 19:23:35 UTC 2016
Pages263
Paragraphs1551
Words48110

Comments